Alkylating Agents in the Treatment of Waldenstrom Macroglobulinemia

被引：1

作者：

Buske, Christian ^{[1
]}

机构：

[1] Univ Hosp Ulm, Comprehens Canc Ctr Ulm, Inst Expt Canc Res, Albert Einstein Allee 1, D-89081 Ulm, Germany

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2018年 / 32卷 / 05期

关键词：

Alkylating agents; Waldenstrom macroglobulinemia; DRC; CHOP; Bendamustine; 1ST-LINE TREATMENT; RITUXIMAB; DEXAMETHASONE; CHOP; CYCLOPHOSPHAMIDE; BENDAMUSTINE; IBRUTINIB; TRIAL;

D O I：

10.1016/j.hoc.2018.05.009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The introduction of ibrutinib has grossly changed the treatment landscape in patients with Waldenstrom macroglobulinemia. Nevertheless, chemotherapy in combination with rituximab is still a cornerstone treatment. Among chemotherapeutics, alkylating agents are most frequently used. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is a highly effective but potentially neurotoxic regimen. Dexamethasone, rituximab, and cyclophosphamide (DRC) induces long responses and has a favorable toxicity profile. Bendamustine was shown to be among the most potent chemotherapeutics in combination with rituximab. Future studies must define the role of alkylating agents, which compete with highly effective chemotherapy-free targeted therapies.

引用

页码：821 / +

页数：9

共 17 条

[1]

Abonour R, 2007, BLOOD, V110, p1058A

[2] How to manage Waldenstrom's macroglobulinemia [J].

Buske, C. ;

Leblond, V. .

LEUKEMIA, 2013, 27 (04) :762-772

[3] The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG) [J].

Buske, C. ;

Hoster, E. ;

Dreyling, M. ;

Eimermacher, H. ;

Wandt, H. ;

Metzner, B. ;

Fuchs, R. ;

Bittenbring, J. ;

Woermann, B. ;

Hohloch, K. ;

Hess, G. ;

Ludwig, W-D ;

Schimke, J. ;

Schmitz, S. ;

Kneba, M. ;

Reiser, M. ;

Graeven, U. ;

Klapper, W. ;

Unterhalt, M. ;

Hiddemann, W. .

LEUKEMIA, 2009, 23 (01) :153-161

[4] Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenstrom macroglobulinaemia [J].

Castillo, Jorge J. ;

Gustine, Joshua N. ;

Meid, Kirsten ;

Dubeau, Toni E. ;

Severns, Patricia ;

Xu, Lian ;

Yang, Guang ;

Hunter, Zachary R. ;

Treon, Steven P. .

BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 (01) :77-85

[5] Primary treatment of Waldenstrom's Macroglobulinemia (WM) with dexamethasone, rituximab and cyclophosphamide. [J].

Dimopoulos, MA ;

Kyrtsonis, MC ;

Tsatalas, C ;

Kokkini, G ;

Repoussis, P ;

Zomas, A ;

Symeonidis, A ;

Michali, E ;

Anagnostopoulos, A ;

Anagnostopoulos, N ;

Economopoulos, T ;

Pangalis, G .

BLOOD, 2004, 104 (11) :215A-215A

[6] Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide [J].

Dimopoulos, Meletios Athanasios ;

Anagnostopoulos, Athanasios ;

Kyrtsonis, Marie-Christine ;

Zervas, Konstantinos ;

Tsatalas, Constantinos ;

Kokkinis, Garyfallia ;

Repoussis, Panagiotis ;

Symeonidis, Argyris ;

Delimpasi, Souzana ;

Katodritou, Eirini ;

Vervessou, Elina ;

Michali, Evridiki ;

Pouli, Anastasia ;

Gika, Dimitra ;

Vassou, Amalia ;

Terpos, Evangelos ;

Anagnostopoulos, Nikolaos ;

Economopoulos, Theophanis ;

Pangalis, Gerasimos .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (22) :3344-3349

[7]

Herold M., 2017, HEMATOL ONCOL, V35, P146, DOI DOI 10.1002/HON.2437_136

[8] Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia: final analysis of a phase 2 study [J].

Kastritis, Efstathios ;

Gavriatopoulou, Maria ;

Kyrtsonis, Marie-Christine ;

Roussou, Maria ;

Hadjiharissi, Evdoxia ;

Symeonidis, Argyris ;

Repoussis, Panagiotis ;

Michalis, Evridiki ;

Delimpasi, Sosana ;

Tsatalas, Konstantinos ;

Tsirigotis, Panagiotis ;

Vassou, Amalia ;

Vervessou, Elina ;

Katodritou, Eirini ;

Gika, Dimitra ;

Terpos, Evangelos ;

Dimopoulos, Meletios A. .

BLOOD, 2015, 126 (11) :1392-1394

[9] Treatment recommendations from the Eighth International Workshop on Waldenstrom's Macroglobulinemia [J].

Leblond, Veronique ;

Kastritis, Efstathios ;

Advani, Ranjana ;

Ansell, Stephen M. ;

Buske, Christian ;

Castillo, Jorge J. ;

Garcia-Sanz, Ramon ;

Gertz, Morie ;

Kimby, Eva ;

Kyriakou, Charalampia ;

Merlini, Giampaolo ;

Minnema, Monique C. ;

Morel, Pierre ;

Morra, Enrica ;

Rummel, Mathias ;

Wechalekar, Ashutosh ;

Patterson, Christopher J. ;

Treon, Steven P. ;

Dimopoulos, Meletios A. .

BLOOD, 2016, 128 (10) :1321-1328

[10] Obinutuzumab for the First-Line Treatment of Follicular Lymphoma [J].

Marcus, R. ;

Davies, A. ;

Ando, K. ;

Klapper, W. ;

Opat, S. ;

Owen, C. ;

Phillips, E. ;

Sangha, R. ;

Schlag, R. ;

Seymour, J. F. ;

Townsend, W. ;

Trneny, M. ;

Wenger, M. ;

Fingerle-Rowson, G. ;

Rufibach, K. ;

Moore, T. ;

Herold, M. ;

Hiddemann, W. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (14) :1331-1344

← 1 2 →